Data Using Carotid Protection Devices Could Drive Shift From Surgery to Stenting

The successful preliminary results of the SAPPHIRE trial--the first study comparing carotid stenting using embolic protection to surgery for carotid artery disease--may drive a shift from surgery to stenting, and may increase adoption of embolic protection devices.

While coronary angioplasty (PTCA) with stenting revolutionized the treatment of coronary artery disease (CAD) and quickly gained widespread adoption, replacing coronary artery bypass graft (CABG) surgery for many patients, carotid angioplasty with stenting remains in its infancy. Twenty years after angioplasty revolutionized coronary revascularization, physicians generally prefer to stick with the surgical gold standard for carotid artery disease, carotid endarterectomy (CEA)—a traumatic but generally successful surgical procedure. That could begin to change, however, with the announcement, at this year's American Heart Association (AHA) meeting held in Chicago in November, of successful preliminary results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) clinical trial.

Driving this shift from surgery to carotid angioplasty is the successful development of embolic protection devices that diminish the likelihood...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Breast Tissue Regeneration: Tensive’s Journey To Restore ‘Wholeness’ For Cancer Survivors

 

Medtech Insight spoke with Sanjay Kakkar, Tensive CEO, about the firm’s breast tissue regeneration implant and its surgical benefits, including a reduced operation time of 74 minutes. He anticipates regulatory approval for Regenera in early 2027.

Mendaera’s Handheld Robotic System Poised To ‘Transform Needle-Based Procedures’ Starting In Urology

 
• By 

After receiving US FDA clearance and reporting first successful use at Mayo Clinic, the Silicon Valley start-up plans to partner with leading centers to transform needle-based procedures with its robotic system starting with urology, then expand into other specialties, the CEO said.

Asabys Partners Talks SafeHeal €10M Investment At LSI Europe

 

SafeHeal has secured an additional €10m for its Colovac device, bringing its total funding to €97.5m. Led by Asabys Partners, this funding offers both economic and clinical benefits, potentially reducing costs and complications associated with temporary stomas.

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

More from R&D

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.